Knock out of α1,3-galactosyltransferase or expression of α1,2- fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection

Transplantation

Volumn 65, Issue 12, 1998, Pages 1599-1604

  Cowan, Peter J ^a   Chen, Chao Guang ^a   Shinkel, Trixie A ^a   Fisicaro, Nella ^a   Salvaris, Evelyn ^a   Aminian, Atousa ^a   Romanella, Margarita ^a   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; FUCOSYLTRANSFERASE; GALACTOSYLTRANSFERASE; BETA D GALACTOSYL N ACETYLGLUCOSAMINYLGLYCOPEPTIDE ALPHA 1,3 GALACTOSYLTRANSFERASE; BETA-D-GALACTOSYL-N-ACETYLGLUCOSAMINYLGLYCOPEPTIDE ALPHA-1,3-GALACTOSYLTRANSFERASE; GALACTOSIDE 2 ALPHA L FUCOSYLTRANSFERASE; GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GRAFT REJECTION; HEART FUNCTION; HEART PERFUSION; HEART TRANSPLANTATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; XENOGRAFT; ANIMAL; GENETICS; HEART MUSCLE; HUMAN; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; FUCOSYLTRANSFERASES; GALACTOSYLTRANSFERASES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIUM; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032572129     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199806270-00010     Document Type: Article

References (41)

1. Leventhal JR, John R, Fryer JP, et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption: results of in vitro and in vivo studies. Transplantation 1995; 59: 294.
2. Kroshus TJ, Bolman RM, Dalmasso AP. Selective IgM depletion prolongs organ survival in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1996; 62: 5.
3. Ye Y, Neethling FA, Niekrasz M, et al. Intravenous administration of alpha-galactosyl carbohydrates reduces in vivo baboon serum cytotoxicity to pig kidney cells and transplanted pig hearts. Transplant Proc 1994; 26: 1399.
4. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
5. Evans MJ, Rollins SA, Wolff DW, et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995; 32: 1183.
6. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
7. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153: 3791.
8. Tearle RG, Tange MJ, Zannettino ZL, et al. The α-1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation 1996; 61: 13.
9. Thall AD, Maly P, Lowe JB. Oocyte Gal alpha 1,3 Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 1995; 270: 21437.
10. Tange MJ, Tearle RG, Aminian A, et al. Demonstration of the functional importance of the Gal epitope in an ex vivo model of xenotransplantation. Xenotransplantation 1997; 4: 20.
11. Chen C-G, Fisicaro N, Shinkel TA, et al. Reduction in Gal-α1,3-Gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplantation 1996; 3: 69.
12. Sharma A, Okabe J, Birch P, et al. Reduction in the level of Gal(alpha 1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase. Proc Natl Acad Sci USA 1996; 93: 7190.
13. Sandrin MS, Fodor WL, Cohney S, et al. Reduction of the major porcine xenoantigen Galα(1,3)Gal by expression of α(1,2)fucosyltransferase. Xenotransplantation 1996; 3: 134.
14. Koike C, Kannagi R, Takuma Y, et al. Introduction of α(1,2)-fucosyltransferase and its effect on α-Gal epitopes in transgenic pig. Xenotransplantation 1996; 3: 81.
15. Chen C-G, Salvaris EJ, Romanella M, et al. Transgenic expression of human α1,2 fucosyltransferase (H transferase) prolongs mouse heart survival in an ex vivo model of xenograft rejection. Transplantation 1998; 65: 832.
16. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
17. Byrne G, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decayaccelerating factor produce an intrinsic barrier to complementmediated damage. Transplantation 1997; 63: 149.
18. Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964.
19. Van Denderen BJW, Pearse MJ, Nottle MB, et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996; 61: 582.
20. Mora M, Mulder LCF, Lazzeri M, et al. Protection from complement-mediated injury in livers and kidneys of transgenic mice expressing human complement regulators. Xenotransplantation 1996; 3: 63.
21. Yannoutsos N, Ijzermans JN, Harkes C, et al. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. Genes Cells 1996; 1: 409.
22. Thorley BR, Milland J, Christiansen D, et al. Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection. Eur J Immunol 1997; 27: 726.
23. Kroshus TJ, Bolman RM, Dalmasso AP, et al. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 1996; 61: 1513.
24. White DJG, Langford GA, Cozzi E, Young VJ. Protective effects of human DAF in transgenic pigs. Xeno 1995; 3: 48.
25. Cowan PJ, Somerville CA, Shinkel TA, et al. High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection. Transplantation 1998; 65: 826.
26. Tange MJ, Salvaris E, Romanella M, et al. Additive effects of CD59 expression in Gal knockout mice in vitro but not in an ex vivo model. Xenotransplantation 1997; 4: 25.
27. van Denderen BJW, Salvaris E, Romanella M, et al. Combination of DAF expression and α1,3 -galactosyltransferase knockout affords added protection from human complement-mediated injury. Transplantation 1997; 64: 882.
28. Cowan PJ, Shinkel TA, Aminian A, et al. High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone. Xenotransplantation (in press).
29. Harrison RA, Lachmann PJ. Complement technology. In: Handbook of experimental immunology and immunochemistry, Vol. 39. Weir D, Herzenberg L, Blackwell C, eds. Oxford: Blackwell Scientific Publications, 1986.
30. Servais G, Walmagh J, Duchateau J. Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50). J Immunol Methods 1991; 140: 93.
31. Cowan PJ, Shinkel TA, Witort EJ, Barlow H, Pearse MJ, d'Apice AJF. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 1996; 62: 155.
32. Platt JL, Logan JS. Use of transgenic animals as xenotransplant donors. In: Xenotransplantation. Cooper DKC, Kemp E, Platt JL, White DJG, eds. Berlin: Springer-Verlag, 1997: 650.
33. Squinto SP, Fodor WL. Engineering of xenografts to provide organs for human transplantation. In: Xenotransplantation. Cooper DKC, Kemp E, Platt JL, White DJG, eds. Berlin: Springer-Verlag, 1997: 659.
34. Cozzi E, Yannoutsos N, Langford GA, Pino-Chavez G, Wallwork J, White DJG. Effect of transgenic expression of human decay accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Xenotransplantation. Cooper DKC, Kemp E, Platt JL, White DJG, eds. Berlin: Springer-Verlag, 1997: 665.
35. Leventhal JR. Removal of natural antibodies by immunoabsorption: results of experimental studies. In: Xenotransplantation. Cooper DKC, Kemp E, Platt JL, White DJG, eds. Berlin: Springer-Verlag, 1997: 360.
36. van Denderen BJW, Pearse MJ, d'Apice AJF. The prospects for renal xenotransplantation. Nephrology 1996; 2: 217.
37. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
38. Diamond LE, McCurry KR, Martin MJ, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 1241.
39. Collins BH, Parker W, Platt JL. Characterization of porcine endothelial cell determinants recognized by human natural antibodies. Xenotransplantation 1994; 1: 36.
40. Shinkel TA, Chen CG, Salvaris E, et al. Changes in cell surface glycosylation in alpha 1,3-galactosyltransferase knock out and alpha 1,2-fucosyltransferase transgenic mice. Transplantation 1997; 64: 197.
41. Galili U, LaTemple DC, Walgenbach AW, Stone KR. Porcine and bovine cartilage transplants in cynomolgus monkey. II. Changes in anti-gal response during chronic rejection. Transplantation 1997; 63: 646.